2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Unknown
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Dermatologic
2
Conditions
Breast Neoplasms
22
Neoplasm Metastasis
15
Carcinoma, Non-Small-Cell Lung
7
Glioblastoma
6
Colorectal Neoplasms
5
Triple Negative Breast Neoplasms
4
Recurrence
4
Ovarian Neoplasms
4
Lymphoma, Mantle-Cell
4
Lymphoma, Follicular
4
Endometrial Neoplasms
4
Brain Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
3
Prostatic Neoplasms
3
Pancreatic Neoplasms
3
Neoplasms
3
Lymphoma, Large B-Cell, Diffuse
3
Lung Neoplasms
3
Hereditary Sensory and Autonomic Neuropathies
3
Head and Neck Neoplasms
3
Solid Tumors
2
Melanoma
2
Lymphoma
2
Leukemia, Myeloid, Acute
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Esophageal Neoplasms
2
Waldenstrom Macroglobulinemia
1
Unspecified Adult Solid Tumor, Protocol Specific
1
Treatment for Metastatic or Locally Advanced Cervical Cancer
1
Tongue Neoplasms
1
Interventions
pembrolizumab
300
Nivolumab
273
Ipilimumab
250
aldesleukin
137
Cyclophosphamide
136
Interleukin-2
105
trametinib
82
dabrafenib
76
Temozolomide
75
Dacarbazine
74
Vemurafenib
71
fludarabine
68
fludarabine phosphate
62
Biopsy
49
binimetinib
47
sargramostim
44
Radiosurgery
44
Bevacizumab
43
Paclitaxel
42
encorafenib
40
incomplete Freund's adjuvant
39
atezolizumab
38
Radiotherapy
37
Cisplatin
36
CTLA-4 Antigen
36
Specimen Handling
35
Magnetic Resonance Spectroscopy
35
Carboplatin
35
cobimetinib
34
Introns
33
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Melanoma
×
NVP-BKM120
×
Clear all
NCT02159066
2024-03-05
LOGIC-2
Pfizer
Phase 2
Completed
158 enrolled
40 charts
NCT02452294
2017-05-03
BUMPER
University Hospital Tuebingen
Phase 2
Unknown
22 enrolled